<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2610200242
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LORINASE-D
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PSEUDOEPHEDRINE HYDROCHLORIDE,DESLORATADINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        120,2.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        OTC
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        24.60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SPIMACO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        R01BA52
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Lorinase-D Extended Release Tablets is a medicinal product contains two active substances: Desloratadine and Pseudoephedrine. Desloratadine is a potent antihistamine with selective peripheral H1-receptor antagonistic activity. Pseudoephedrine sulfate, one of the naturally occurring alkaloids of Ephedra and an orally administered vasoconstrictor, produces a gradual but sustained decongestant effect facilitating shrinkage of congested mucosa in upper respiratory areas. The mucous membrane of the respiratory tract is decongested through the action of the sympathetic nerves.</p><p>&nbsp;</p><p>Lorinase-D Extended Release Tablets relieves symptoms associated with allergic rhinitis (hay fever) in adults and adolescents 12 years of age and older, such as:</p><p>&nbsp;</p><p>&bull; Nasal and sinus congestion.</p><p>&nbsp;</p><p>&bull; Sneezing.</p><p>&nbsp;</p><p>&bull; Runny nose.</p><p>&nbsp;</p><p>&bull; Watery, itchy eyes.</p><p>&nbsp;</p><p>Lorinase-D Extended Release Tablets contains a combination of two medicines: Desloratadine (an antihistamine) and pseudoephedrine (a decongestant).</p><p>&nbsp;</p><p>Antihistamines help reduce allergic symptoms by preventing the effects of a substance called histamine. Histamine is produced by the body in response to foreign substances which the body is allergic to. Decongestants produce narrowing of blood vessels. This leads to clearing of the stuffy or blocked nose.</p><p>&nbsp;</p><p>Your doctor or pharmacist, however, may prescribe Lorinase-D Extended Release Tablets for another purpose. Ask your doctor or pharmacist if you have any questions about why Lorinase-D Extended Release Tablets has been prescribed for you.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Who should not take this medicine?</strong></p><p><strong>Do not take Lorinase-D Extended Release Tablets if you:</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Have an allergy to Lorinase-D Extended Release Tablets or any of the ingredients listed at the end of this leaflet.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Are allergic to loratadine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Have narrow-angle glaucoma.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Have problems with urination (urinary retention).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take a Monoamine Oxidase Inhibitor (MAOI) medicine to treat depression, or if you stopped taking an MAOI medicine within the last 2 weeks. Ask your doctor or pharmacist if you are not sure if you take an MAOI medicine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Have severe high blood pressure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Have severe heart disease.</p><p>&nbsp;</p><p>Talk to your doctor before taking this medicine if you have any of these conditions.</p><p>Do not take Lorinase-D Extended Release Tablets if the packaging is torn or shows signs of tampering.</p><p><strong>&nbsp;</strong></p><p><strong>Before you start to take it, tell your doctor or pharmacist if you:</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Have any of the conditions listed in the section &quot;Who should not take this medicine?&quot;</p><ul><li>Have diabetes</li><li>Have hyperthyroidism</li><li>Have prostate problems</li><li>Have liver or kidney problems</li><li>Have any other medical conditions</li><li>Are pregnant or plan to become pregnant. It is not known if Lorinase-D Extended Release Tablets will harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant.</li><li>Are breastfeeding or plan to breastfeed. Lorinase-D Extended Release Tablets <strong>can pass into your breast milk</strong>. Talk to your doctor about the best way to feed your baby if you take Lorinase-D Extended Release Tablets.</li></ul><p>&nbsp;</p><p>Take a special care before you take this medicine:</p><p>&nbsp;</p><p>As with other CNS stimulants, pseudoephedrine sulphate carries the risk of abuse. Increased doses may ultimately produce toxicity. Continuous use can lead to tolerance resulting in an increased risk of overdosing.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Taking other medicines:</strong></p><p><strong>Tell your doctor about all the medicines you take,</strong>&nbsp;including prescription and nonprescription medicines, vitamins and herbal supplements. Lorinase-D Extended Release Tablets may affect the way other medicines work, and other medicines may affect how Lorinase-D Extended Release Tablets works. Especially tell your doctor if you take:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Monoamine Oxidase Inhibitors (MAOIs). You should not use Lorinase-D Extended Release Tablets if you take an MAOI or within 2 weeks of stopping an MAOI.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Methyldopa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reserpine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Digoxin, ketoconazole</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; erythromycin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; azithromycin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; antihistamines</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other decongestant medicines</p><p>Know the medicines you take. Keep a list of your medicines and show it to your doctor and pharmacist when you get a new medicine.</p><p>The pseudoephedrine in Lorinase-D Extended Release Tablets is considered a stimulant by sporting bodies. Its use in competing athletes is not recommended.</p><p>&nbsp;</p><p><strong>Taking Lorinase-D Extended Release Tablets with food</strong></p><p>It does not matter if you take Lorinase-D Extended Release Tablets before or after food.</p><p>&nbsp;</p><p><strong>Pediatric Use </strong></p><p>LORINASE-D Extended Release Tablets are not indicated for use in pediatric patients under 12 years of age.</p><p><strong>Renal Impairment </strong></p><p>LORINASE-D Extended Release Tablets should generally be avoided in patients with renal impairment.</p><p><strong>Hepatic Impairment </strong></p><p>LORINASE-D Extended Release Tablets should generally be avoided in patients with hepatic impairment.</p><p><strong>Driving and using machines</strong></p><p>Make sure you know how you react to Lorinase-D Extended Release Tablets before you drive a car or operate machinery.</p><p>Lorinase-D Extended Release Tablets is unlikely to make you drowsy. If you are drowsy, do not drive a car or work with machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>How much to take</strong></p><p><strong>&nbsp;</strong></p><p>Take Lorinase-D Extended Release Tablets exactly as your doctor tells you to take it.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lorinase-D Extended Release Tablets can be taken with or without food.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swallow Lorinase-D Extended Release Tablet whole.&nbsp;<strong>Do not break, crush, or chew</strong>&nbsp;Lorinase-D Extended Release Tablet before swallowing. If you cannot swallow Lorinase-D Extended Release Tablet whole, tell your doctor. You may need a different medicine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take&nbsp;<strong>1</strong>&nbsp;Lorinase-D Extended Release Tablet 2 times a day (every 12 hours).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use in children under 12 years of age.</p><p><strong>&nbsp;</strong></p><p>Consult your doctor if symptoms did not improve within 7 days or if symptoms were associated with fever.</p><p>&nbsp;</p><p>Do not take more Lorinase-D Extended Release Tablets than recommended by your doctor or pharmacist.</p><p><strong>If you forget to take it</strong></p><p>If it is almost time for your next dose, skip the dose you missed and take your next dose when you are meant to.</p><p>Otherwise, take it as soon as you remember, and then go back to taking your medicine as you would normally. Do not take a double dose to make up for the dose you missed.</p><p><strong>If you take too much (overdose)</strong></p><p>Immediately telephone your doctor for advice or go to casualty at your nearest hospital, if you think that you or anyone else may have taken too much Lorinase-D Extended Release Tablets. Do this even if there are no signs of discomfort or poisoning. You may need urgent medical attention.</p><p>&nbsp;</p><p><strong>Stop taking Lorinase-D Extended Release Tablets 48 hours before you have any skin tests.</strong></p><p><strong>&nbsp;</strong></p><p>Antihistamines may interfere with the results of skin tests.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Lorinase-D Extended Release Tablets<strong> </strong>may cause serious side effects, including:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cardiovascular and central nervous system effects, such as</p><p>o&nbsp;&nbsp; unable to sleep (insomnia)</p><p>o&nbsp;&nbsp; dizziness</p><p>o&nbsp;&nbsp; weakness</p><p>o&nbsp;&nbsp; tremor</p><p>o&nbsp;&nbsp; irregular heart beat</p><p>o&nbsp;&nbsp; seizure</p><p>o&nbsp;&nbsp; low blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased sleepiness or tiredness can happen if you take more Lorinase-D Extended Release Tablets<strong> </strong>than your doctor prescribed to you.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reactions. Stop taking Lorinase-D Extended Release Tablets<strong> </strong>and call your doctor right away or get emergency help if you have any of these symptoms:</p><p>o&nbsp;&nbsp; rash</p><p>o&nbsp;&nbsp; itching</p><p>o&nbsp;&nbsp; hives</p><p>o&nbsp;&nbsp; swelling of your lips, tongue, face, and throat</p><p>o&nbsp;&nbsp; shortness of breath or trouble breathing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe skin reactions including signs and symptoms such as fever, reddening of the skin, or many small pimples</p><ul><li>Rarely: sudden onset of severe headache, nausea, vomiting or visual disturbances which may be symptoms of conditions known as Posterior Reversible Encephalopathy Syndrome (PRES) or Reversible Cerebral Vasoconstriction Syndrome (RCVS).</li></ul><p>The most common side effects of Lorinase-D Extended Release Tablets<strong> </strong>include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unable to sleep (insomnia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sore throat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dry mouth</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sleepiness</p><p>Tell your doctor if you have any side effect that bothers you or that does not go away.</p><p>These are not all of the possible side effects of Lorinase-D Extended Release Tablets. For more information, ask your doctor or pharmacist.</p><p>Tell your doctor or pharmacist as soon as possible if you do not feel well while you are using Lorinase-D Extended Release Tablets.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>&nbsp;</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Keep your tablets in the blister pack in a dry place until it is time to take them.</strong></p><p><strong>&nbsp;</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you take your tablets out of the blister pack they will not keep well.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store below 30<sup>○</sup>C.</p><p><strong>&nbsp;</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not store them or any other medicine in the bath room or near a sink.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not leave them in the car on hot days or on window sills.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep out of the reach and sight of children.</p><p><strong>&nbsp;</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your doctor or pharmacist tells you to stop taking Lorinase-D Extended Release Tablets or the tablets have passed their expiry date, ask your pharmacist what to do with any tablets that are left over.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>For Lorinase-D Extended Release Tablets:</strong></p><p>Lorinase-D Extended Release tablet is a round, flat beveled edge, uncoated bilayer tablet, having mottled on blue color with &quot;276&quot; at one side and white plain surface on the other side.</p><p>&nbsp;</p><p>Nature and contents of container: 20/pack in 2 blisters, each blister contains 10 tablets.</p><p>Blisters: Reel PVC/PE/PVDC 250/25/120, 95MM Clear blister.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                For Lorinase-D Extended Release Tablets tablet:
Active ingredients: Desloratadine 2.5mg and Pseudoephedrine sulfate 120mg.

Other ingredients:
For PSEUDOEPHEDRINE SULFATE 120 MG BULK
•	Dibasic Calcium Phosphate Dihydrate, 
•	Avicel PH 102,
•	Hydroxypropyl Methylcellulose K15M,
•	Povidone 30,
•	Purified Water BP: Q.S.

-	Extragranular Materials
•	Colloidal Silicon Dioxide,
•	Magnesium Stearate.

For DESLORATADINE 2.5 MG BULK
•	Avicel PH 101,
•	Maize Starch,
•	Pregelatinized Starch Dry,
•	Spectracol Brilliant Blue LK 815030,
•	Purified Water BP Q.S.

-	Extragranular Materials
•	Pregelatinized Starch Dry,
•	Avicel PH 112,
•	Colloidal Silicon Dioxide,
•	Sodium Stearyl Fumarate.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>SPIMACO</strong></p><p>Al-Qassim Pharmaceutical Plant</p><p>Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                March 2024.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">لورينيز-د أقراص ممتدة المفعول هو مستحضر دوائي يحتوي على مادتين فعالتين هما: ديسلوراتادين وسودوإفيدرين.</p><p dir="RTL">ديسلوراتادين هو مضاد للهيستامين قوي طويل المفعول له تأثير اختياري مضاد لمستقبلات H1 الطرفية. أما كبريتات السودوإفيدرين، فهو واحد من قلويدات الإفيدرا الموجودة في الطبيعة وهو مضيق للأوعية الدموية يعطي بالفم، وينتج عنه أثر تدريجي مزيل للاحتقان، ولكنه ممتد، فيسهل انكماش الغشاء المخاطي المحتقن في مناطق الجهاز التنفسي العليا. وتتم إزالة الاحتقان من الغشاء المخاطي للسبيل التنفسي من خلال مفعوله على الأعصاب الودية (السمبثاوية).</p><p dir="RTL">لورينيز-د أقراص ممتدة المفعول يخفف من الأعراض المصاحبة لحساسية الأنف (حمى القش) لدى البالغين والمراهقين في سن 12 سنة من العمر فما أكثر مثل:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احتقان الأنف والجيوب الأنفية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العطس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيلان الأنف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة في العيون مع زيادة الدموع.</p><p dir="RTL">لورينيز-د أقراص ممتدة المفعول يحتوي على مزيج من دوائين هما: ديسلوراتادين (مضاد للهيستامين) و سودوافيدرين (مزيل للاحتقان).</p><p dir="RTL">مضادات الهيستامين تساعد على تقليل أعراض الحساسية بمنع تأثير مادة تسمي الهيستامين. ينتج الهيستامين في الجسم كرد فعل لوجود أجسام غريبة يتحسس لها الجسم. مزيلات الاحتقان تقوم بتضييق الأوعية الدموية. وهذا يؤدي إلي تصفية الأنف غير جيدة التهوية أو المسدودة.</p><p dir="RTL">قد يقوم طبيبك المعالج أو الصيدلي بوصف لورينيز-د أقراص ممتدة المفعول لسبب آخر. اسأل طبيبك المعالج أو الصيدلي إذا كانت لديك أي أسئلة حول سبب وصف لورينيز-د أقراص ممتدة المفعول لك.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>من يجب عليه عدم تناول هذا الدواء؟</strong></p><p dir="RTL"><strong>لا تتناول لورينيز-د أقراص ممتدة المفعول فى الحالات الآتية:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصاباً بالحساسية تجاه لورينيز-د أقراص ممتدة المفعول أو أي من المكونات المذكورة في نهاية هذه النشرة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصاباً بالحساسية تجاه مادة اللوراتادين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من زيادة ضغط العين ذو الزاوية الضيقة (الزرق ضيق الزاوية).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل بالتبول (احتباس البول).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أدوية مثبطة لإنزيم أحادي الأمين والتي تستخدم لعلاج الاكتئاب، أو إذا توقفت عن تناول تلك الأدوية خلال آخر أسبوعين. اسأل طبيبك المعالج أو الصيدلي إذا كنت غير متأكداً من أنك تعالج بهذه الأدوية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من ارتفاع حاد في ضغط الدم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض حاد بالقلب.</p><p dir="RTL">تحدث إلى طبيبك المعالج قبل البدء في تناول هذا الدواء إذا كان لديك أي مما سبق ذكره.</p><p dir="RTL">لا تتناول لورينيز-د أقراص ممتدة المفعول إذا كانت العبوة ممزقة أو ظهر عليها علامات العبث.</p><p dir="RTL"><strong>قبل البدء في تناول هذا الدواء، أخبر طبيبك أو الصيدلي في الحالات الآتية:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك أي مما سبق ذكره في الفقرة &quot; من يجب عليه عدم تناول هذا الدواء؟&quot;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصاباً بمرض السكر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من فرط نشاط الغدة الدرقية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك مشاكل بالبروستاتا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك مشاكل بالكبد أو الكلى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من أي مشاكل طبية أخرى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ حاملاً أو تخططين للحمل. حيث من غير المعروف مدى ضرر تأثير هذا الدواء على الجنين. تحدثي إلى طبيبك المعالج إذا كنتِ حاملاً أو تخططين للحمل.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ ترضعين طفلك طبيعياً أو تخططين لذلك. حيث يتم إفراز أقراص لورينيز-د ممتدة المفعول في لبن الثدي. تواصلي مع طبيبك المعالج بشأن أفضل طريقة لإرضاع طفلك أثناء فترة تناولك هذا الدواء.</p><p dir="RTL">انتبه جيدًا قبل تناول هذا الدواء:</p><p dir="RTL">كما هو الحال مع المنشطات الأخرى للجهاز العصبي المركزي، تحمل كبريتات سودوإيفيدرين خطر سوء الاستخدام. قد تؤدي الجرعات الزائدة في النهاية إلى تسمم. يمكن أن يؤدي الاستخدام المستمر إلى نقص الاستجابة للعلاج مما يؤدي إلى زيادة خطر الجرعات الزائدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول أدوية أخرى</strong></p><p dir="RTL">أخبر طبيبك المعالج بشأن كل الأدوية التي تتناولها، سواء تلك التي حصلت علىها بوصفة طبية أو بدون، مثل الفيتامينات أو المكملات الغذائية العشبية. حيث قد يؤثر هذا الدواء في طريقة عمل بعض الأدوية، وأيضاً قد تؤثر بعض الأدوية على طريقة عمل هذا الدواء. على وجه الخصوص أخبر طبيبك المعالج إذا كنت تتناول أياً مما يلي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثبطات إنزيم أحادي الأمين. يجب عليك عدم استخدام هذا الدواء إذا كنت تستخدم مثبطات إنزيم أحادي الأمين أو توقفت عن استخدامها خلال الأسبوعين الماضيين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميثيل دوبا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريسيربين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ديجوكسين, أو كيتوكونازول.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إريثروميسين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أزيثروميسين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الحساسية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية أخرى مزيلة للاحتقان.</p><p dir="RTL">يجب علىك معرفة الأدوية التي تستخدمها. احتفظ بقائمة تشمل الأدوية التي تستخدمها وقم بعرضها على طبيبك المعالج أو الصيدلي عند حصولك على دواء جديد.</p><p dir="RTL">يعتبر السودوإفيدرين المتواجد في لورينيز-د أقراص ممتدة المفعول كمنشط من قبل الهيئات الرياضية. لا ينصح باستخدامه في الرياضيين المتنافسين.</p><p dir="RTL"><strong>تناول لورينيز-د أقراص ممتدة المفعول مع الطعام</strong></p><p dir="RTL">لا يهم تناول لورينيز-د أقراص ممتدة المفعول قبل أو بعد الطعام.</p><p dir="RTL"><strong>الاستخدام في الأطفال</strong></p><p dir="RTL">لا يستخدم لورينيز-د أقراص ممتدة المفعول في الأطفال المرضى تحت سن 12 سنة من العمر.</p><p dir="RTL"><strong>القصور الكلوي</strong></p><p dir="RTL">يجب تجنب استخدام لورينيز-د أقراص ممتدة المفعول في المرضى الذين يعانون من القصور الكلوي بشكل عام.</p><p dir="RTL"><strong>القصور الكبدي</strong></p><p dir="RTL">يجب تجنب استخدام لورينيز-د أقراص ممتدة المفعول في المرضى الذين يعانون من اختلال كبدي بشكل عام.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">كن متأكداً من معرفتك عن مدى رد فعلك تجاه لورينيز-د أقراص ممتدة المفعول قبل قيادتك للسيارة أو تشغيل الماكينات. من غير المرجح أن يتسبب لك لورينيز-د أقراص ممتدة المفعول في النعاس. إذا كنت في حالة من النعاس، لا تقود السيارة أو تقوم بالعمل مع الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الجرعة الموصى بها</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قم بتناول أقراص لورينيز-د ممتدة المفعول تماماً كما أخبرك طبيبك المعالج.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن تناول هذه الأقراص مع أو بدون الطعام.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قم بابتلاع القرص كاملاً. لا تقم بتكسير أو مضغ القرص قبل ابتلاعه. في حالة عدم قدرتك على بلع القرص كاملاً، أخبر طبيبك المعالج. فقد تحتاج إلى علاج آخر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قم بتناول قرص واحد من هذا الدواء مرتين يومياً (كل 12 ساعة).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمنع استخدام هذا الدواء للأطفال الأقل في العمر من 12 سنة.</p><p dir="RTL">استشِر طبيبك المعالج إذا لم تتحسن لديك الأعراض خلال 7 أيام أو إذا كانت الأعراض مصحوبة بحمي.</p><p dir="RTL">لا تقم بتناول لورينيز-د أقراص ممتدة المفعول أكثر مما أوصي به طبيبك أو الصيدلي.</p><p dir="RTL"><strong>إذا نسيت أن تتناول لورينيز-د أقراص ممتدة المفعول</strong></p><p dir="RTL">إذا كان الوقت هو تقريباً وقت الجرعة التالية، قم بتخطي الجرعة التي نسيتها وقم بتناول الجرعة التالية في وقتها.</p><p dir="RTL">خلاف ذلك، تناول الجرعة حالما تتذكر، وبعد ذلك قم بتناول دوائك كالمعتاد. لا تقم بتناول جرعة مضاعفة لتعويض الجرعة المنسية.</p><p dir="RTL"><strong>إذا تناولت لورينيز-د أقراص ممتدة المفعول أكثر مما يجب (جرعة مفرطة)</strong></p><p dir="RTL">اتصل في الحال بطبيبك للاستشارة أو توجه إلى قسم الطوارئ في أقرب مستشفى، إذا اعتقدت أنك أنت أو أي شخص آخر قد تناول الكثير من لورينيز-د أقراص ممتدة المفعول. قم بذلك حتى ولو لم تظهر أي أعراض من عدم الراحة أو التسمم. فقد تكون هناك حاجة إلى رعاية طبية عاجلة.</p><p dir="RTL"><strong>توقف عن تناول لورينيز-د أقراص ممتدة المفعول </strong><strong>48</strong><strong> ساعة قبل إجراء أي اختبار جلدي للحساسية.</strong></p><p dir="RTL">مضادات الهيستامين من الممكن أن تتداخل مع نتائج الاختبارات الجلدية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قد تسبب أقراص لورينيز-د ممتدة المفعول أعراضاً جانبية خطيرة، تشمل:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تأثيرات على القلب والأوعية الدموية و الجهاز العصبي المركزي، مثل:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم القدرة على النوم (أرق).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رعشة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم انتظام ضربات القلب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يحدث ازدياد النعاس أو الإرهاق في حالة تناولك جرعة أكبر من تلك الموصوفة لك من أقراص لورينيز-د ممتدة المفعول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات تحسسية. توقف عن تناول أقراص لورينيز-د ممتدة المفعول وتواصل مع طبيبك المعالج أو اطلب الرعاية الطبية الطارئة إذا تعرضت لأي من الأعراض التالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة بالجلد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشرى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم بالشفتين، اللسان، الوجه، والحلق.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق أو صعوبة بالتنفس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات جلدية حادة تشمل أعراض مثل الحمى أو احمرار الجلد أو ظهور بثور جلدية عديدة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع شديد مفاجئ &nbsp;أو الغثيان أو القيء أو الاضطرابات البصرية التي قد تكون أعراضًا لحالات تعرف باسم متلازمة اعتلال الدماغ الخلفي القابل للانعكاس (PRES) أو متلازمة تضيق الأوعية الدماغية العكسية (RCVS). ]<em>العكسية بمعنى قابلة للعلاج</em>[.</p><p dir="RTL">الأعراض الجانبية الأكثر شيوعاً لأقراص لورينيز-د ممتدة المفعول، تشمل:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم القدرة على النوم (أرق).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الحلق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف الفم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إرهاق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نعاس.</p><p dir="RTL">أخبر طبيبك المعالج إذا تعرضت لأي أعراض جانبية مزعجة أو مستمرة.</p><p dir="RTL">قد لا تمثل هذه الأعراض الجانبية كل الأعراض الجانبية محتملة الحدوث لهذا الدواء. لمزيد من المعلومات، اسأل طبيبك المعالج أو الصيدلي.</p><p dir="RTL">أخبر طبيبك أو الصيدلي في أقرب وقت ممكن إذا لم تشعر أنك على ما يرام أثناء تناولك لورينيز-د أقراص ممتدة المفعول.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>قم بحفظ الأقراص في العبوة الخاصة بها في مكان جاف حتى ميعاد تناولها.</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا قمت بأخذ الأقراص خارج العبوة فهذا قد يتسبب في عدم حفظها جيداً.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تقم بحفظ&nbsp; هذا الدواء أو أي أدوية أخري في الحمام أو قرب المغسلة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تقم بترك الدواء في السيارة في الأيام الحارة أو على حافة الشباك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ بعيداً عن متناول ونظر الأطفال.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أخبرك طبيبك أو الصيدلي بأن تتوقف عن تناول لورينيز-د أقراص ممتدة المفعول أو إذا تجاوزت الأقراص تاريخ الصلاحية، اسأل الصيدلي عما يجب القيام به مع الأقراص المتبقية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>بالنسبة ل لورينيز-د أقراص ممتدة المفعول أقراص</strong></p><p dir="RTL">قرص لورينيز-د ممتد المفعول هو قرص دائري، ذو حافة مسطحة مشطوفة غير مصقولة ذو طبقتين، مرقش على اللون الأزرق مع رقم &quot;276&quot; في جانب واحد وسطح عادي أبيض على الجانب الآخر.</p><p dir="RTL">عبوات الأقراص: 20 قرصاً لكل عبوة مقسمة على شريطين، يحتوي الشريط على 10 أقراص.</p><p dir="RTL">حاويات الأقراص: شرائط شفافة من مادة PVC/PE/PVDC 250/25/120, 95MM &nbsp;.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>بالنسبة ل لورينيز-د أقراص ممتدة المفعول أقراص:</strong></p><p dir="RTL">المادة الفعالة هي:ديسلوراتادين 2.5 &nbsp;ملجم و كبريتات السودوإفيدرين 120 ملجم.</p><p dir="RTL">المكونات الأخري هي:</p><p dir="RTL"><strong>لكتلة كبريتات السودوإفيدرين 120 ملجم: </strong><strong>&nbsp;</strong></p><p dir="RTL">&bull; ثنائي القاعدة كالسيوم فوسفات ثنائي الهيدرات.</p><p dir="RTL">&bull; أفيسل PH 102</p><p dir="RTL">&bull; هيدروكسي بروبيل ميثيل سيليلوز K15M</p><p dir="RTL">&bull; بوفيدون 30</p><p dir="RTL">&bull; ماء مقطر.</p><p dir="RTL">- مواد خاصة بالطبقة الخارجية للحبيبات:</p><p dir="RTL">&bull; ثاني أكسيد السليكون الصمغي.</p><p dir="RTL">&bull; ستيرات المغنيسيوم.</p><p dir="RTL"><strong>لكتلة ال ديسلوراتادين 2.5 ملجم:</strong></p><p dir="RTL">&bull; أفيسل PH 101</p><p dir="RTL">&bull; نشا الذرة.</p><p dir="RTL">&bull; النشا الجاف قبل مرحلة تكوين الجيلاتين.</p><p dir="RTL">&bull; سبيكتراكول الزرقاء اللامعة LK 815030</p><p dir="RTL">&bull; ماء مقطر.</p><p dir="RTL">- مواد خاصة بالطبقة الخارجية للحبيبات:</p><p dir="RTL">&bull; النشا الجاف قبل مرحلة تكوين الجيلاتين.</p><p dir="RTL">&bull; أفيسل PH 112</p><p dir="RTL">&bull; ثاني أكسيد السليكون الصمغي.</p><p dir="RTL">&bull; صوديوم ستياريل فيومارات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الدوائية</strong></p><p dir="RTL">مصنع الأدوية بالقصيم</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            مارس 2024.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lorinase-D 2.5/120 mg extended release tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Active ingredients: Desloratadine 2.5mg and Pseudoephedrine sulfate 120mg.
For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Extended Release Tablet
A round, flat beveled edge, uncoated bilayer tablet, having mottled on blue color with "276" at one side and white plain surface on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lorinase-D<sup> </sup>Extended Release Tablet is indicated for the relief of the nasal and non-nasal symptoms of seasonal allergic rhinitis, including nasal congestion, in adults and adolescents 12 years of age and older. Lorinase-D<sup> </sup>Extended Release Tablets should be administered when the antihistaminic properties of desloratadine and the nasal decongestant properties of pseudoephedrine are desired.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Administer Lorinase-D Extended Release Tablet by the oral route only. Do not break, chew, or crush the tablet. Swallow the tablet whole.</p><p>&nbsp;</p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Adults and children aged 12 years or more: </strong></p><p>The recommended dose of Lorinase-D Extended Release Tablet is 1 tablet twice a day, administered approximately 12 hours apart and with or without a meal. Higher doses or increased dosing frequency of Lorinase-D Extended Release Tablets have not demonstrated increased effectiveness. Do not exceed the recommended dose as desloratadine and pseudoephedrine, the active components of Lorinase-D Extended Release Tablets have been associated with adverse effects at higher doses.</p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                LORINASE-D Extended Release Tablets are contraindicated in:
•	Patients with hypersensitivity to any of its ingredients, or to loratadine [see Warnings and Precautions and Adverse Reactions.] 
•	Patients with narrow-angle glaucoma.
•	Patients with urinary retention.
•	Patients receiving monoamine oxidase (MAO) inhibitor therapy or within fourteen (14) days of stopping such treatment [see Drug Interactions]. 
•	Patients with cardiovascular diseases, such as for example: Coronary ischemia, tachyarrhythmia, severe hypertension and severe coronary artery disease or hyperthyroidism.

Lorinase-D Extended Release Tablets should not be given to children under the age of 12 years.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In patients taking digitalis, patients with cardiac arrhythmias, hypertension, myocardial infarction, diabetes, stenosing peptic ulcer, pyloroduodenal obstruction, prostatic hypertrophy or bladder neck obstruction, or bronchospasm in patients with a history of caution. Special caution is required in patients aged 60 years or more, it is for people in this age group are more likely adverse reactions to sympathomimetics. In this case, the dose should be reduced. The dose should be reduced in the case of severe renal insufficiency.</p><p>&nbsp;</p><p>Caution should be exercised in patients treated with other sympathomimetic agents, including decongestants, drugs to reduce appetite or amphetamine-type stimulant medications, antihypertensives, tricyclic antidepressants and other antihistamines.</p><p>&nbsp;</p><p>As with any CNS stimuli are also in pseudoephedrine sulfate reported abuse. Prolonged use can lead to tolerance and therefore increases the risk of over-dosing.</p><p>&nbsp;</p><p>The effect of the results of laboratory test results: Antihistamines should be discontinued approximately 2 days before skin tests because they can prevent or reduce otherwise positive reaction to the skin indicators.</p><p>Lorinase-D medicine may affect your test taking doping in athletes.</p><p>&nbsp;</p><p>As with other CNS stimulants, pseudoephedrine sulphate carries the risk of abuse. Increased doses may ultimately produce toxicity. Continuous use can lead to tolerance resulting in an increased risk of overdosing.</p><p>&nbsp;</p><p>&nbsp;</p><p>There have been rare cases of posterior reversible encephalopathy syndrome (PRES) / reversible cerebral vasoconstriction syndrome (RCVS) reported with sympathomimetic drugs, including pseudoephedrine.</p><p>Symptoms reported include sudden onset of severe headache, nausea, vomiting, and visual disturbances. Most cases improved or resolved within a few days following appropriate treatment. Pseudoephedrine should be discontinued, and medical advice sought immediately if signs or symptoms of PRES/RCVS develop.</p><p>Pseudoephedrine-containing medicines must not be used in patients with severe or uncontrolled hypertension or severe acute or chronic kidney disease or renal failure, as these are risk factors for developing PRES or RCVS.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Cardiovascular and Central Nervous System Effects </strong></p><p>The pseudoephedrine sulfate contained in LORINASE-D Extended Release Tablets, like other sympathomimetic amines, can produce cardiovascular and central nervous system (CNS) effects in some patients such as insomnia, dizziness, weakness, tremor, or arrhythmias. In addition, central nervous system stimulation with convulsions or cardiovascular collapse with accompanying hypotension has been reported. Therefore, LORINASE-D Extended Release Tablets should be used with caution in patients with cardiovascular disorders, and should not be used in patients with severe hypertension or severe coronary artery disease.</p><p>&nbsp;</p><p><strong>Coexisting Conditions </strong></p><p>LORINASE-D Extended Release Tablets contain pseudoephedrine sulfate, a sympathomimetic amine, and therefore should be used with caution in patients with diabetes and hyperthyroidism. Also use with caution in patients with prostatic hypertrophy or increased intraocular pressure, as urinary retention and narrow-angle glaucoma may occur [see Contraindications (4.3)].</p><p>&nbsp;</p><p><strong>Co-Administration with Monoamine Oxidase (MAO) Inhibitors </strong></p><p>LORINASE-D Extended Release Tablets should not be used in patients receiving monoamine oxidase (MAO) inhibitor therapy or within fourteen (14) days of stopping such treatment as an increase in blood pressure or hypertensive crisis, may occur [see Contraindications (4.3) and Drug Interactions (4.5)].</p><p>&nbsp;</p><p><strong>Hypersensitivity Reactions </strong></p><p>Hypersensitivity reactions including rash, pruritus, urticaria, edema, dyspnea, and anaphylaxis have been reported after administration of desloratadine a component of LORINASE-D Extended Release Tablets. If such a reaction occurs, therapy with LORINASE-D Extended Release Tablets should be stopped and alternative treatment should be considered [see Adverse Reactions (4.8)].</p><p>&nbsp;</p><p><strong>Renal Impairment </strong></p><p>LORINASE-D Extended Release Tablets should generally be avoided in patients with renal impairment.</p><p>&nbsp;</p><p><strong>Hepatic Impairment </strong></p><p>LORINASE-D Extended Release Tablets should generally be avoided in patients with hepatic impairment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No specific interaction studies have been conducted with LORINASE-D Extended Release Tablets.</p><p><strong>&nbsp;</strong></p><p><strong>Monoamine Oxidase Inhibitors </strong></p><p>LORINASE-D Extended Release Tablets should not be used in patients receiving monoamine oxidase (MAO) inhibitor therapy or within fourteen (14) days of stopping such treatment because the action of pseudoephedrine a component of LORINASE-D Extended Release tablets on the vascular system may be potentiated by these agents [see Contraindications (4.3) and Warnings and Precautions (4.4)].</p><p>&nbsp;</p><p><strong>Beta-Adrenergic Blocking Agents </strong></p><p>The antihypertensive effects of beta-adrenergic blocking agents, methyldopa, and reserpine, may be reduced by sympathomimetics such as pseudoephedrine. Exercise caution when using LORINASE-D Extended Release Tablets with these agents.</p><p>&nbsp;</p><p><strong>Digitalis </strong></p><p>Increased ectopic pacemaker activity can occur when pseudoephedrine is used concomitantly with digitalis. Exercise caution when using LORINASE-D Extended Release Tablets with these agents.</p><p>&nbsp;</p><p><strong>Inhibitors of Cytochrome P450 3A4 </strong></p><p>In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3-hydroxydesloratadine but there were no clinically relevant changes in the safety profile of desloratadine.</p><p>&nbsp;</p><p><strong>Fluoxetine </strong></p><p>In controlled clinical studies co-administration of desloratadine with fluoxetine, a selective serotonin reuptake inhibitor (SSRI), resulted in increased plasma concentrations of desloratadine and 3-hydroxydesloratadine but there were no clinically relevant changes in the safety profile of desloratadine.</p><p><em>&nbsp;</em></p><p><strong>Cimetidine </strong></p><p>In controlled clinical studies co-administration of desloratadine with cimetidine a histamine H2-receptor antagonist resulted in increased plasma concentrations of desloratadine and 3-hydroxydesloratadine but there were no clinically relevant changes in the safety profile of desloratadine.</p><p><strong>&nbsp;</strong></p><p><u>Desloratadine:</u> Concomitant use of alcohol, Desloratadine does not increase its activities, which are research assessed by measurements of physical and mental fitness.</p><p>&nbsp;</p><p>Following concomitant administration of ketoconazole, erythromycin, or cimetidine in controlled clinical trials reported an increase in plasma concentrations of Desloratadine but without clinically significant changes (including changes in the ECG). Other drugs known to inhibit hepatic metabolism should only be used concurrently with caution until definitive studies are completed drug-drug interactions.</p><p>&nbsp;</p><p><u>Pseudoephedrine: </u>Sympathomimetics may reduce the antihypertensive effect of drugs affecting the sympathetic system as example. methyldopa, reserpine, and guanethidine, and partially counteract the hypotensive effects of beta blockers. Concomitant use of tablets Lorinase-D with sympathomimetic agents such as, for example: decongestants, drugs used to reduce appetite, amphetamines, tricyclic antidepressants or MAO inhibitors may increase blood pressure. Due to the long-term operation MAO inhibitors, this effect can also be 14 days after discontinuation of treatment (see section 4.3). Concomitant use of furazolidone should be avoided as it may cause a dose-dependent brake MAO. Concomitant use of pseudoephedrine and digitalis may result in increased ectopic activity centers in the heart. Antacids increase the rate of pseudoephedrine absorption, kaolin decreases it.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Pediatric Use </strong></p><p>LORINASE-D Extended Release Tablets are not indicated for use in pediatric patients under 12 years of age.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Geriatric Use </strong></p><p>The number of subjects (n=10) &ge;65 years old treated with LORINASE-D Extended Release Tablets was too limited to make any formal statistical comparison regarding the efficacy or safety of this drug product in this age group, or to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences between the elderly and younger patients, although the elderly are more likely to have adverse reactions to sympathomimetic amines. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p><p>&nbsp;</p><p>Pseudoephedrine, desloratadine, and their metabolites are known to be substantially excreted by the kidney, and the risk of adverse reactions may be greater in patients with renal impairment. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor the patient for adverse events.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Renal Impairment </strong></p><p>No studies with LORINASE-D Extended Release Tablets were conducted in subjects with renal impairment. LORINASE-D Extended Release Tablets should generally be avoided in patients with renal impairment [see Warnings and Precautions (4.4)].</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Hepatic Impairment </strong></p><p>No studies with LORINASE-D Extended Release Tablets or pseudoephedrine were conducted in subjects with hepatic impairment. LORINASE-D Extended Release Tablets should generally be avoided in patients with hepatic impairment [see Warnings and Precautions (4.4)].</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Gender </strong></p><p>No clinically significant gender-related differences were observed in the pharmacokinetic parameters of desloratadine, 3-hydroxydesloratadine or pseudoephedrine following administration of LORINASE-D Extended Release Tablets.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Race </strong></p><p>No studies have been conducted to evaluate the effect of race on the pharmacokinetics of LORINASE-D Extended Release Tablets.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy </strong></p><p><strong>Pregnancy Category C: </strong>There are no adequate and well-controlled studies of desloratadine and pseudoephedrine in combination in pregnant women. Neither are there animal reproduction studies conducted with the combination of desloratadine and pseudoephedrine. Desloratadine was not teratogenic in rats or rabbits but affected implantation in rats. Because animal reproduction studies are not always predictive of human response, LORINASE-D Extended Release Tablets should be used during pregnancy only if clearly needed.</p><p>Desloratadine was not teratogenic in rats or rabbits at approximately 210 and 230 times, respectively, the AUC in humans at the recommended daily oral dose. An increase in pre-implantation loss and a decreased number of implantations and fetuses were noted, however, in a separate study in female rats at approximately 120 times the AUC in humans at the recommended daily oral dose. Reduced body weight and slow righting reflex were reported in pups at approximately 50 times or greater than the AUC in humans at the recommended daily oral dose. Desloratadine had no effect on pup development at approximately 7 times the AUC in humans at the recommended daily oral dose. The AUCs in comparison referred to the desloratadine exposure in rabbits and the sum of desloratadine and its metabolites exposures in rats, respectively [see Nonclinical Toxicology (13.2)].</p><p><em>&nbsp;</em></p><p><strong>Lactation</strong></p><p>Desloratadine and pseudoephedrine both pass into breast milk; therefore, a decision should be made whether to discontinue nursing or to discontinue LORINASE-D Extended Release Tablets, taking into account the benefit of the drug to the nursing mother and the possible risk to the child.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>At a daily dose of 10 mg of Desloratadine were reported sedating the operation of the product. Attention and reaction time were not reduced. Similarly, it is not known that pseudoephedrine sulfate decreased psychophysical ability.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reported adverse reactions by system organ class in MedDRA</p><p>Very common (&ge; 1/10); Common (&ge; 1/100 to &lt;1/10); uncommon (&ge; 1/1000 to &lt;1/100); Rare (&ge; 1/10, 000 to &lt;1/1000); very rare (&lt;1/10, 000)</p><p>&nbsp;</p><p><strong>Metabolism and nutrition disorders </strong></p><p>Common: thirst.</p><p><strong>Psychiatric disorders </strong></p><p>Very common: anorexia, insomnia.</p><p>Common: nervousness, somnolence, depression, agitation.</p><p><strong>Nervous system disorders </strong></p><p>Very common: dry mouth.</p><p>Common: dizziness.</p><p>Uncommon: confusion, tremors, increased sweating, hot flushes, broken flavor.</p><p><strong>Eye Disorders </strong></p><p>Uncommon: disorders of lacrimal gland.</p><p><strong>Ear and labyrinth disorders </strong></p><p>Uncommon: tinnitus</p><p><strong>Heart disease </strong></p><p>Common: tachycardia</p><p>Uncommon: palpitations</p><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p><p>Common: pharyngitis, rhinitis</p><p>Uncommon: epistaxis</p><p><strong>Gastrointestinal Disorders </strong></p><p>Common: constipation, nausea</p><p><strong>Renal and urinary disorders </strong></p><p>Uncommon: micturition disorders</p><p><strong>Skin and subcutaneous tissue disorders </strong></p><p>Common: pruritus</p><p><strong>General disorders and administration site conditions </strong></p><p>Common: headache, chills.</p><p>&nbsp;</p><p>Other adverse reactions have been reported very rarely during post-marketing are listed below:</p><p><strong>Immune system disorders: </strong>anaphylaxis</p><p><strong>Nervous system disorders: </strong>vertigo</p><p><strong>Vascular diseases: </strong>hypertension</p><p><strong>Respiratory, thoracic and mediastinal disorders: </strong>cough, bronchospasm</p><p><strong>Hepato-biliary disorders: </strong>abnormal liver function</p><p><strong>Renal and urinary disorders: </strong>urinary retention</p><p><strong>Skin and subcutaneous tissue disorders: </strong>alopecia</p><p>&nbsp;</p><p>The following adverse reactions are discussed in greater detail in other sections of the label:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cardiovascular and Central Nervous System effects [see Warnings and Precautions (4.4)]</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased intraocular pressure [see Warnings and Precautions (4.4)]</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Urinary retention in patients with prostatic hypertrophy [see Warnings and Precautions (4.4)]</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypersensitivity reactions [see Warnings and Precautions (4.4)]</p><p>&nbsp;</p><p><strong>Clinical Trials Experience </strong></p><p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p><p>&nbsp;</p><p>The safety data described below are from 2 clinical trials with LORINASE-D Extended Release Tablets that included 1248 patients with seasonal allergic rhinitis, of which 414 patients received LORINASE-D Extended Release Tablets twice daily for up to 2 weeks. The majority of patients were between 18 and &lt;65 years of age with a mean age of 35.8 years and were predominantly women (64%). Patient ethnicity was 82% Caucasian, 9% Black, 6% Hispanic and 3% Asian/other ethnicity. The percentage of subjects receiving LORINASE-D Extended Release Tablets and who discontinued from the clinical trials because of an adverse event was 3.6%. Adverse reactions that were reported by &ge;2% of subjects receiving LORINASE-D Extended Release Tablets are shown in <strong>Table 1.</strong></p><p><strong>&nbsp;</strong></p><p><strong>Table 1: Incidence of Adverse Reactions Reported by &ge;2% of Subjects Receiving LORINASE-D Extended Release Tablets</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Adverse Reaction </strong></p></td><td style="vertical-align:top"><p><strong>LORINASE-D BID (N=414) </strong></p></td><td style="vertical-align:top"><p><strong>Desloratadine 5 mg QD (N=412) </strong></p></td><td style="vertical-align:top"><p><strong>Pseudoephedrine 120 mg BID (N=422) </strong></p></td></tr><tr><td><p><strong><em>Gastrointestinal Disorders </em></strong></p></td><td colspan="3"><p>&nbsp;</p></td></tr><tr><td><p>Mouth Dry</p></td><td style="vertical-align:bottom"><p>8%</p></td><td style="vertical-align:bottom"><p>2%</p></td><td style="vertical-align:bottom"><p>8%</p></td></tr><tr><td><p>Nausea</p></td><td style="vertical-align:bottom"><p>2%</p></td><td style="vertical-align:bottom"><p>1%</p></td><td style="vertical-align:bottom"><p>3%</p></td></tr><tr><td><p><strong><em>General Disorders and Administration Site Conditions </em></strong></p></td><td colspan="3"><p>&nbsp;</p></td></tr><tr><td><p>Fatigue</p></td><td style="vertical-align:bottom"><p>4%</p></td><td style="vertical-align:bottom"><p>2%</p></td><td style="vertical-align:bottom"><p>2%</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Metabolism and Nutrition Disorders </em></strong></p></td><td colspan="3"><p>&nbsp;</p></td></tr><tr><td><p>Anorexia</p></td><td style="vertical-align:bottom"><p>2%</p></td><td style="vertical-align:bottom"><p>0%</p></td><td style="vertical-align:bottom"><p>2%</p></td></tr><tr><td><p><strong><em>Nervous System Disorders </em></strong></p></td><td colspan="3"><p>&nbsp;</p></td></tr><tr><td><p>Headache</p></td><td style="vertical-align:bottom"><p>8%</p></td><td style="vertical-align:bottom"><p>8%</p></td><td style="vertical-align:bottom"><p>9%</p></td></tr><tr><td><p>Somnolence</p></td><td style="vertical-align:bottom"><p>3%</p></td><td style="vertical-align:bottom"><p>4%</p></td><td style="vertical-align:bottom"><p>2%</p></td></tr><tr><td><p>Dizziness</p></td><td style="vertical-align:bottom"><p>3%</p></td><td style="vertical-align:bottom"><p>2%</p></td><td style="vertical-align:bottom"><p>2%</p></td></tr><tr><td><p><strong><em>Psychiatric Disorders </em></strong></p></td><td colspan="3"><p>&nbsp;</p></td></tr><tr><td><p>Insomnia</p></td><td style="vertical-align:bottom"><p>10%</p></td><td style="vertical-align:bottom"><p>3%</p></td><td style="vertical-align:bottom"><p>13%</p></td></tr><tr><td><p><strong><em>Respiratory, Thoracic, and Mediastinal Disorders </em></strong></p></td><td colspan="3"><p>&nbsp;</p></td></tr><tr><td><p>Pharyngitis</p></td><td style="vertical-align:bottom"><p>3%</p></td><td style="vertical-align:bottom"><p>3%</p></td><td style="vertical-align:bottom"><p>3%</p></td></tr></tbody></table><p>&nbsp;</p><p>There were no relevant differences in adverse reactions for subgroups of patients as defined by gender, age, or race.</p><p>&nbsp;</p><p><strong>Post-Marketing Experience </strong></p><p>In addition to the adverse reactions reported during clinical trials and listed above, adverse events have been identified during post approval use of LORINASE-D Extended Release Tablets. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Adverse events identified from post-marketing surveillance on the use of LORINASE-D Extended Release Tablets include tachycardia, palpitations, dyspnea, rash and pruritus.</p><p>In addition to these events, the following spontaneous adverse events have been reported during the marketing of desloratadine as a single ingredient product: headache, somnolence, dizziness and rarely hypersensitivity reactions (such as urticaria, edema and anaphylaxis), psychomotor hyperactivity, movement disorders (including dystonia, tics, and extrapyramidal symptoms), seizures, and elevated liver enzymes including bilirubin and, very rarely, hepatitis.</p><p>&nbsp;</p><p>Other adverse reactions reported during post-marketing only to Desloratadine include increased appetite, redness and gastritis.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Pediatric Use </strong></p><p>LORINASE-D Extended Release Tablets are not indicated for use in pediatric patients under 12 years of age.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Geriatric Use </strong></p><p>The number of subjects (n=10) &ge;65 years old treated with LORINASE-D Extended Release Tablets was too limited to make any formal statistical comparison regarding the efficacy or safety of this drug product in this age group, or to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences between the elderly and younger patients, although the elderly are more likely to have adverse reactions to sympathomimetic amines. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p><p>&nbsp;</p><p>Pseudoephedrine, desloratadine, and their metabolites are known to be substantially excreted by the kidney, and the risk of adverse reactions may be greater in patients with renal impairment. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor the patient for adverse events.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Renal Impairment </strong></p><p>No studies with LORINASE-D Extended Release Tablets were conducted in subjects with renal impairment. LORINASE-D Extended Release Tablets should generally be avoided in patients with renal impairment [see Warnings and Precautions (4.4)].</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Hepatic Impairment </strong></p><p>No studies with LORINASE-D Extended Release Tablets or pseudoephedrine were conducted in subjects with hepatic impairment. LORINASE-D Extended Release Tablets should generally be avoided in patients with hepatic impairment [see Warnings and Precautions (4.4)].</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Gender </strong></p><p>No clinically significant gender-related differences were observed in the pharmacokinetic parameters of desloratadine, 3-hydroxydesloratadine or pseudoephedrine following administration of LORINASE-D Extended Release Tablets.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Race </strong></p><p>No studies have been conducted to evaluate the effect of race on the pharmacokinetics of LORINASE-D Extended Release Tablets.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>DRUG ABUSE AND DEPENDENCE </strong></p><p>There is no information to indicate that abuse or dependency occurs with LORINASE-D or LORINASE-D Extended Release Tablets.</p><p>&nbsp;</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p><strong>To Report Side Effects:</strong></p><p><strong>For Saudi Arabia:</strong></p><p> The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2340.</p><p>o Reporting hotline: 19999.</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: https://ade.sfda.gov.sa</p><p><strong>For UAE:</strong></p><p>Pharmacovigilance &amp; Medical Device section</p><p>P.O.Box: 1853</p><p>Tel: 80011111</p><p>Email: pv@mohap.gov.ae</p><p>Drug Department</p><p>Ministry of Health &amp; Prevention,</p><p>Dubai</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>For OMAN:</strong></p><p>Department of Pharmacovigilance &amp; Drug Information</p><p>Directorate General of Pharmaceutical Affairs &amp; Drug Control</p><p>Ministry of Health, Sultanate of Oman</p><p>Phone Nos. 22357687 / 22357686</p><p>Fax: 22358489</p><p>Email: dg-padc@moh.gov.om</p><p>Website: www.moh.gov.om</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the event of overdose, consider standard measures to remove any unabsorbed drug. Symptomatic and supportive treatment is recommended. Desloratadine and 3-hydroxydesloratadine are not eliminated by hemodialysis.</p><p><strong>&nbsp;</strong></p><p><strong>Desloratadine </strong></p><p>Information regarding acute overdosage with desloratadine is limited to experience from post-marketing adverse event reports and from clinical trials conducted during the development of the LORINASE-D product. In the reported cases of overdose, there were no significant adverse events that were attributed to desloratadine. In a dose-ranging trial, at doses of 10 mg and 20 mg/day, somnolence was reported.</p><p>&nbsp;</p><p>In another study, no clinically relevant adverse events were reported in normal male and female volunteers who were given single daily doses of LORINASE-D 45 mg for 10 days [see Clinical Pharmacology (12.2)].</p><p>&nbsp;</p><p>Lethality occurred in rats at oral doses of 250 mg/kg or greater (estimated desloratadine and desloratadine metabolite exposures were approximately 120 times the AUC in humans at the recommended daily oral dose). The oral median lethal dose in mice was 353 mg/kg (estimated desloratadine exposure was approximately 290 times the human daily oral dose on an mg/m2 basis). No deaths occurred at oral doses up to 250 mg/kg in monkeys (estimated desloratadine exposure was approximately 810 times the human daily oral dose on an mg/m2 basis).</p><p>&nbsp;</p><p><strong>Sympathomimetics </strong></p><p>In large doses, sympathomimetics such as pseudoephedrine may give rise to giddiness, headache, nausea, vomiting, sweating, thirst, tachycardia, precordial pain, palpitations, difficulty in micturition, muscle weakness and tenseness, anxiety, restlessness, and insomnia. Many patients can present a toxic psychosis with delusions and hallucinations. Some may develop cardiac arrhythmias, circulatory collapse, convulsions, coma, and respiratory failure.</p><p>&nbsp;</p><p>The probability of CNS stimulation is particularly high in children, and this also applies to signs and symptoms similar to those seen after atropine (dry mouth, dilated pupils unresponsive, flushing, hyperthermia, and gastrointestinal symptoms).</p><p>&nbsp;</p><p><u>Treatment:</u> The patient vomiting, even if it is already vomited spontaneously. The best way to challenge vomiting using syrup of ipecac. In patients with disorders of consciousness, vomiting should not be induced. Precautions must be taken against aspiration of vomit, especially in children. After vomiting may try to adsorb the remaining amount of drug in the stomach, so that the patient administered the active carbon in the form of a mixture with water.</p><p>&nbsp;</p><p>If vomiting is unsuccessful or contraindicated if it is necessary to carry out gastric lavage. The solution of choice for this purpose is a saline solution, particularly in children, while in adults may be used as drinking water. Before the next instillation should be removed as big as possible intake of medicines.</p><p>&nbsp;</p><p>Salt laxatives pull water into the intestines on the principle of osmosis and therefore may be useful due to the rapid dilution of bowel content.</p><p>&nbsp;</p><p>It is not known, or can be administered to remove by dialysis.</p><p>&nbsp;</p><p>After emergency treatment, the patient continued to remain under medical supervision. Treatment of the signs and symptoms of overdose is symptomatic and supportive. Stimulants (analeptiki) should not be used. Hypertension can be controlled with alpha blockers, tachycardia with beta-blockers. Short-acting barbiturates - diazepam 10 mg i.v. or i.m. (adults) and 0.5 mg / kg intrarectally (children), or paraldehyde - can be used for the control of possible seizures. In hyperpyrexia, especially in children, may require lowering the body temperature by washing with a sponge soaked in lukewarm water, or hypothermic blanket. Apnea is treated with ventilatory support.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Mechanism of Action </strong></p><p>Desloratadine is a long acting tricyclic histamine antagonist with selective H1-receptor histamine antagonist activity. Receptor binding data indicate that at a concentration of 2 to 3 ng/mL (7 nanomolar), desloratadine shows significant interaction with the human histamine H1 receptor. Desloratadine inhibited histamine release from human mast cells in vitro. Results of a radiolabeled tissue distribution study in rats and a radioligand H1-receptor-binding study in guinea pigs showed that desloratadine does not readily cross the blood brain barrier. The clinical significance of this finding is unknown.</p><p>&nbsp;</p><p>Pseudoephedrine sulfate is an orally active sympathomimetic amine and exerts a decongestant action on the nasal mucosa. Pseudoephedrine sulfate is recognized as an effective agent for the relief of nasal congestion due to allergic rhinitis. Pseudoephedrine produces peripheral effects similar to those of ephedrine and central effects similar to, but less intense than, amphetamines. It has the potential for excitatory side effects.</p><p><strong>&nbsp;</strong></p><p><strong>Wheal and Flare:</strong> Human histamine skin wheal studies following single and repeated 5 mg doses of desloratadine have shown that the drug exhibits an antihistaminic effect by 1 hour; this activity may persist for as long as 24 hours. There was no evidence of histamine-induced skin wheal tachyphylaxis within the desloratadine 5 mg group over the 28-day treatment period. The clinical relevance of histamine wheal skin testing is unknown.</p><p>&nbsp;</p><p><strong>Effects on QTc:</strong> In clinical trials for LORINASE-D Extended Release Tablets, ECGs were recorded at baseline and endpoint within 1 to 3 hours after the last dose. The majority of ECGs were normal at both baseline and endpoint. No clinically meaningful changes were observed following treatment with LORINASE-D Extended Release Tablets for any ECG parameter, including the QTc interval. An increase in the ventricular rate of 7.1 and 6.4 bpm was observed in the LORINASE-D Extended Release Tablets and pseudoephedrine groups, respectively, compared to an increase of 3.2 bpm in subjects receiving desloratadine alone. Single daily doses of LORINASE-D 45 mg were given to normal male and female volunteers for 10 days.</p><p>&nbsp;</p><p>All ECGs obtained in this study were manually read in a blinded fashion by a cardiologist. In the LORINASE-D-treated subjects, there was a mean increase in the maximum heart rate of 9.2 bpm relative to placebo. The QT interval was corrected for heart rate (QTc) by both Bazett&rsquo;s and Fridericia methods. Using the QTc (Bazett), there was a mean increase of 8.1 msec in the LORINASE-D-treated subjects relative to placebo. Using QTc (Fridericia) there was a mean increase of 0.4 msec in LORINASE-D-treated subjects relative to placebo. No clinically relevant adverse events were reported.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>CLINICAL STUDIES </strong></p><p><strong>&nbsp;</strong></p><p><strong>Seasonal Allergic Rhinitis </strong></p><p>The clinical efficacy and safety of LORINASE-D Extended Release Tablets was evaluated in two 2-week multicenter, randomized parallel group clinical trials involving 1248 subjects 12 to 78 years of age with seasonal allergic rhinitis, 414 of whom received LORINASE-D Extended Release Tablets. In the 2 trials, subjects were randomized to receive LORINASE-D Extended Release Tablets twice daily, LORINASE-D Tablets 5 mg once daily, or sustained-release pseudoephedrine tablet 120 mg twice daily for 2 weeks. The majority of patients were between 18 and &lt;65 years of age with a mean age of 35.8 years and were predominantly women (64%). Patient ethnicity was 82% Caucasian, 9% Black, 6% Hispanic and 3% Asian/other ethnicity. Primary efficacy variable was twice-daily reflective patient scoring of 4 nasal symptoms (rhinorrhea, nasal stuffiness/congestion, nasal itching, and sneezing) and four non-nasal symptoms (itching/burning eyes, tearing/watering eyes, redness of eyes, and itching of ears/palate) on a 4 point scale (0=none, 1=mild, 2=moderate, and 3=severe). In both trials, the antihistaminic efficacy of LORINASE-D Extended Release Tablets, as measured by total symptom score excluding nasal congestion, was significantly greater than pseudoephedrine alone over the 2-week treatment period; and the decongestant efficacy of LORINASE-D Extended Release Tablets, as measured by nasal stuffiness/congestion, was significantly greater than LORINASE-D (desloratadine alone) over the 2-week treatment period. Primary efficacy variable results from 1 of 2 trials are shown in <strong>Table 3.</strong></p><p>&nbsp;</p><p><strong>Table 3: Changes in Symptoms in a 2-Week Clinical Trial in Subjects With Seasonal Allergic Rhinitis</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Treatment Group (n) </strong></p></td><td style="vertical-align:top"><p><strong>Mean Baseline* (SEM) </strong></p></td><td style="vertical-align:top"><p><strong>Change (% Change) from Baseline&dagger; (SEM) </strong></p></td><td style="vertical-align:top"><p><strong>LORINASE-D Comparison to Components&Dagger; (<em>P</em>-value) </strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Total Symptom Score (Excluding Nasal Congestion)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>LORINASE-D Extended Release Tablets BID (199) </strong></p></td><td style="vertical-align:top"><p>14.18 (0.21)</p></td><td style="vertical-align:top"><p>-6.54 (-46.0) (0.30)</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>Pseudoephedrine tablet 120 mg BID (197) </strong></p></td><td style="vertical-align:top"><p>14.06 (0.21)</p></td><td style="vertical-align:top"><p>-5.07 (-35.9) (0.30)</p></td><td style="vertical-align:top"><p><strong><em>P</em></strong><strong>&lt;0.001 </strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>LORINASE-D 5 mg Tablets QD (197) </strong></p></td><td style="vertical-align:top"><p>14.82 (0.21)</p></td><td style="vertical-align:top"><p>-5.09 (-33.5) (0.30)</p></td><td style="vertical-align:top"><p><em>P</em>&lt;0.001</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Nasal Stuffiness/Congestion</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>LORINASE-D Extended Release Tablets BID (199) </strong></p></td><td style="vertical-align:top"><p>2.47 (0.027)</p></td><td style="vertical-align:top"><p>-0.93 (-37.4) (0.046)</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>Pseudoephedrine tablet 120 mg BID (197) </strong></p></td><td style="vertical-align:top"><p>2.46 (0.027)</p></td><td style="vertical-align:top"><p>-0.75 (-31.2) (0.046)</p></td><td style="vertical-align:top"><p><em>P</em>=0.006</p></td></tr><tr><td style="vertical-align:top"><p><strong>LORINASE-D 5 mg Tablets QD (197) </strong></p></td><td style="vertical-align:top"><p>2.50 (0.027)</p></td><td style="vertical-align:top"><p>-0.66 (-26.7) (0.046)</p></td><td style="vertical-align:top"><p><strong><em>P</em></strong><strong>&lt;0.001 </strong></p></td></tr></tbody></table><p>&nbsp;</p><p>SEM=Standard Error of the Mean</p><p>* To qualify at Baseline, the sum of the twice-daily diary reflective scores for the 3 days prior to Baseline and the morning of the Baseline visit were to total &ge;42 for total nasal symptom score (sum of 4 nasal symptoms of rhinorrhea, nasal stuffiness/congestion, nasal itching, and sneezing) and a total of &ge;35 for total non-nasal symptoms score (sum of 4 non-nasal symptoms of itching/burning eyes, tearing/watering eyes, redness of eyes, and itching of ears/palate), and a score of &ge;14 for each of the individual symptoms of nasal stuffiness/congestion and rhinorrhea. Each symptom was scored on a 4-point severity scale (0=none, 1=mild, 2=moderate, 3=severe).</p><p>&dagger; Mean reduction in score averaged over the 2-week treatment period.</p><p>&Dagger; The comparison of interest is shown bolded.</p><p>There were no significant differences in the efficacy of LORINASE-D Extended Release Tablets across subgroups of subjects defined by gender, age, or race.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption:</strong> In a single dose pharmacokinetic study, the mean time to maximum plasma concentrations (Tmax) for desloratadine occurred at approximately 4 to 5 hours post dose and mean peak plasma concentrations (Cmax) and area under the concentration-time curve (AUC) of approximately 1.09 ng/mL and 31.6 nghr/mL, respectively, were observed. In another pharmacokinetic study, food and grapefruit juice had no effect on the bioavailability (Cmax and AUC) of desloratadine.</p><p>For pseudoephedrine, the mean Tmax occurred at 6 to 7 hours post dose and mean peak plasma concentrations (Cmax) and area under the concentration-time curve (AUC) of approximately 263 ng/mL and 4588 nghr/mL, respectively, were observed. Food had no effect on the bioavailability (Cmax and AUC) of pseudoephedrine.</p><p>Following oral administration of LORINASE-D Extended Release Tablets twice daily for 14 days in healthy volunteers, steady-state conditions were reached on Day 10 for desloratadine, 3-hydroxydesloratadine and pseudoephedrine. For desloratadine, mean steady-state peak plasma concentrations (Cmax) and area under the concentration-time curve AUC 0-12 hrs of approximately 1.7 ng/mL and 16 ng&bull;hr/mL were observed, respectively. For pseudoephedrine, mean steady-state peak plasma concentrations (Cmax) and AUC 0-12 hrs of 459 ng/mL and 4658 ng&bull;hr/mL were observed.</p><p>&nbsp;</p><p><strong>Distribution:</strong> Desloratadine and 3-hydroxydesloratadine are approximately 82% to 87% and 85% to 89%, bound to plasma proteins, respectively. Protein binding of desloratadine and 3-hydroxydesloratadine was unaltered in subjects with impaired renal function.</p><p>&nbsp;</p><p><strong>Metabolism:</strong> Desloratadine (a major metabolite of loratadine) is extensively metabolized to 3-hydroxydesloratadine, an active metabolite, which is subsequently glucuronidated. The enzyme(s) responsible for the formation of 3-hydroxydesloratadine have not been identified. Data from clinical trials with desloratadine indicate that a subset of the general population has a decreased ability to form 3-hydroxydesloratadine, and are poor metabolizers of desloratadine. In pharmacokinetic studies (n=3748), approximately 6% of subjects were poor metabolizers of desloratadine (defined as a subject with an AUC ratio of 3-hydroxydesloratadine to desloratadine less than 0.1, or a subject with a desloratadine half-life exceeding 50 hours). These pharmacokinetic studies included subjects between the ages of 2 and 70 years, including 977 subjects aged 2 to 5 years, 1575 subjects aged 6 to 11 years, and 1196 subjects aged 12 to 70 years. There was no difference in the prevalence of poor metabolizers across age groups. The frequency of poor metabolizers was higher in Blacks (17%, n=988) as compared to Caucasians (2%, n=1462) and Hispanics (2%, n=1063). The median exposure (AUC) to desloratadine in the poor metabolizers was approximately 6-fold greater than in the subjects who are not poor metabolizers. Subjects who are poor metabolizers of desloratadine cannot be prospectively identified and will be exposed to higher levels of desloratadine following dosing with the recommended dose of desloratadine. In multidose clinical safety studies, where metabolizer status was prospectively identified, a total of 94 poor metabolizers and 123 normal metabolizers were enrolled and treated with LORINASE-D Syrup for 15 to 35 days. In these studies, no overall differences in safety were observed between poor metabolizers and normal metabolizers. Although not seen in these studies, an increased risk of exposure-related adverse events in patients who are poor metabolizers cannot be ruled out.</p><p>Pseudoephedrine alone is incompletely metabolized (less than 1%) in the liver by N-demethylation to an inactive metabolite. The drug and its metabolite are excreted in the urine. About 55% to 96% of an administered dose of pseudoephedrine hydrochloride is excreted unchanged in the urine.</p><p>&nbsp;</p><p><strong>Elimination: </strong>Following single dose administration of LORINASE-D Extended Release Tablets, the mean plasma elimination half-life of desloratadine was approximately 27 hours. In another study, following administration of single oral doses of desloratadine 5 mg, Cmax and AUC values increased in a dose proportional manner following single oral doses between 5 and 20 mg. The degree of accumulation after 14 days of dosing was consistent with the half-life and dosing frequency. A human mass balance study documented a recovery of approximately 87% of the 14C-desloratadine dose, which was equally distributed in urine and feces as metabolic products. Analysis of plasma 3-hydroxydesloratadine showed similar Tmax and half-life values compared to desloratadine.</p><p>The mean elimination half-life of pseudoephedrine is dependent on urinary pH. The elimination half-life is approximately 3 to 6 or 9 to 16 hours when the urinary pH is 5 or 8, respectively.</p><p>&nbsp;</p><p><strong>Geriatric Subjects:</strong> Following multiple-dose administration of LORINASE-D Tablets, the mean Cmax and AUC values for desloratadine were 20% greater than in younger subjects (˂ 65 years old). The oral total body clearance (CL/F) when normalized for body weight was similar between the 2 age groups. The mean plasma elimination half-life of desloratadine was 33.7 hr in subjects &ge; 65 years old. The pharmacokinetics for 3-hydroxydesloratadine appeared unchanged in older vs. younger subjects. These age-related differences are unlikely to be clinically relevant and no dosage adjustment is recommended in elderly patients.</p><p>&nbsp;</p><p><strong>Pediatric Subjects:</strong> LORINASE-D Extended Release Tablets are not an appropriate dosage form for use in pediatric patients below 12 years of age.</p><p>&nbsp;</p><p><strong>Renally Impaired:</strong> Following a single dose of desloratadine 7.5 mg, pharmacokinetics were characterized in subjects with mild (n=7; creatinine clearance 51-69 mL/min/1.73 m2), moderate (n=6; creatinine clearance 34-43 mL/min/1.73 m2) and severe (n=6; creatinine clearance 5-29 mL/min/1.73 m2) renal impairment or hemodialysis dependent (n=6) subjects. In subjects with mild and moderate renal impairment, median Cmax and AUC values increased by approximately 1.2-and 1.9-fold, respectively, relative to subjects with normal renal function. In subjects with severe renal impairment or who were hemodialysis dependent, Cmax and AUC values increased by approximately 1.7-and 2.5-fold, respectively. Minimal changes in 3hydroxydesloratadine concentrations were observed. Desloratadine and 3-hydroxydesloratadine were poorly removed by hemodialysis. Plasma protein binding of desloratadine and 3-hydroxydesloratadine was unaltered by renal impairment.</p><p>Pseudoephedrine is primarily excreted unchanged in the urine as unchanged drug with the remainder apparently being metabolized in the liver. Therefore, pseudoephedrine may accumulate in patients with renal impairment.</p><p>&nbsp;</p><p><strong>Hepatically Impaired:</strong> Following a single oral dose of desloratadine, pharmacokinetics were characterized in subjects with mild (n=4), moderate (n=4) and severe (n=4) hepatic impairment as defined by the Child-Pugh classification of hepatic impairment and 8 subjects with normal hepatic function. Subjects with hepatic impairment, regardless of severity, had approximately a 2.4-fold increase in AUC as compared with normal subjects. The apparent oral clearance of desloratadine in subjects with mild, moderate, and severe hepatic impairment was 37%, 36%, and 28% of that in normal subjects, respectively. An increase in the mean elimination half-life of desloratadine in subjects with hepatic impairment was observed. For 3hydroxydesloratadine, the mean Cmax and AUC values for subjects with hepatic impairment combined were not statistically significantly different from subjects with normal hepatic function.</p><p>&nbsp;</p><p><strong>Gender:</strong> Female subjects treated for 14 days with LORINASE-D Tablets had 10% and 3% higher desloratadine Cmax and AUC values, respectively, compared with male subjects. The 3-hydroxydesloratadine Cmax and AUC values were also increased by 45% and 48%, respectively, in females compared with males. However, these apparent differences are not considered to be clinically relevant.</p><p>&nbsp;</p><p><strong>Race: </strong>Following 14 days of treatment with LORINASE-D Tablets, the Cmax and AUC values for desloratadine were 18% and 32% higher, respectively in Blacks compared with Caucasians. For 3-hydroxydesloratadine there was a corresponding 10% reduction in Cmax and AUC values in Blacks compared to Caucasians. These differences are not considered to be clinically relevant.</p><p>&nbsp;</p><p><strong>Drug Interaction:</strong> In 2 controlled crossover clinical pharmacology studies in healthy male (n=12 in each study) and female (n=12 in each study) subjects, desloratadine 7.5 mg (1.5 times the daily dose) once daily was co-administered with erythromycin 500 mg every 8 hours or ketoconazole 200 mg every 12 hours for 10 days. In 3 separate controlled, parallel group clinical pharmacology studies, desloratadine at the clinical dose of 5 mg has been co-administered with azithromycin 500 mg followed by 250 mg once daily for 4 days (n=18) or with fluoxetine 20 mg once daily for 7 days after a 23-day pretreatment period with fluoxetine (n=18) or with cimetidine 600 mg every 12 hours for 14 days (n=18) under steady state conditions to healthy male and female subjects. Although increased plasma concentrations (Cmax and AUC<sub>0-24</sub> hrs) of desloratadine and 3-hydroxydesloratadine were observed (see <strong>Table 2</strong>), there were no clinically relevant changes in the safety profile of desloratadine, as assessed by electrocardiographic parameters (including the corrected QT interval), clinical laboratory tests, vital signs and adverse events.</p><p>&nbsp;</p><p><strong>Table 2: Changes in Desloratadine and 3-hydroxydesloratadine Pharmacokinetics in Healthy Male and Female Subjects </strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td colspan="2" style="vertical-align:top"><p><strong><u>Desloratadine</u></strong></p></td><td colspan="2" style="vertical-align:top"><p><strong><u>3-hydroxydesloratadine</u></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong>Cmax</strong></p></td><td style="vertical-align:top"><p><strong>AUC <sub>0-24 </sub>hrs</strong></p></td><td style="vertical-align:top"><p><strong>Cmax</strong></p></td><td style="vertical-align:top"><p><strong>AUC <sub>0-24 </sub>hrs</strong></p></td></tr><tr><td style="vertical-align:top"><p>Erythromycin</p><p>(500 mg Q8h)</p></td><td style="vertical-align:top"><p>+24%</p></td><td style="vertical-align:top"><p>+14%</p></td><td style="vertical-align:top"><p>+43%</p></td><td style="vertical-align:top"><p>+40%</p></td></tr><tr><td style="vertical-align:top"><p>Ketoconazole</p><p>(200 mg Q12h)</p></td><td style="vertical-align:top"><p>+45%</p></td><td style="vertical-align:top"><p>+39%</p></td><td style="vertical-align:top"><p>+43%</p></td><td style="vertical-align:top"><p>+72%</p></td></tr><tr><td style="vertical-align:top"><p>Azithromycin</p><p>(500 mg Day 1,</p><p>250 mg QD x 4 days)</p></td><td style="vertical-align:top"><p>+15%</p></td><td style="vertical-align:top"><p>+5%</p></td><td style="vertical-align:top"><p>+15%</p></td><td style="vertical-align:top"><p>+4%</p></td></tr><tr><td style="vertical-align:top"><p>Fluoxetine</p><p>(20 mg QD)</p></td><td style="vertical-align:top"><p>+15%</p></td><td style="vertical-align:top"><p>+0%</p></td><td style="vertical-align:top"><p>+17%</p></td><td style="vertical-align:top"><p>+13%</p></td></tr><tr><td style="vertical-align:top"><p>Cimetidine</p><p>(600 mg Q12h)</p></td><td style="vertical-align:top"><p>+12%</p></td><td style="vertical-align:top"><p>+19%</p></td><td style="vertical-align:top"><p>-11%</p></td><td style="vertical-align:top"><p>-3%</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>5.3.1 Carcinogenesis, Mutagenesis, Impairment of Fertility </strong></p><p>There are no animal or laboratory studies on the combination product of desloratadine and pseudoephedrine sulfate to evaluate carcinogenesis, mutagenesis, or impairment of fertility.</p><p>&nbsp;</p><p><strong>Carcinogenicity Studies:</strong> The carcinogenic potential of desloratadine was assessed using a loratadine study in rats and a desloratadine study in mice. In a 2-year study in rats, loratadine was administered in the diet at doses up to 25 mg/kg/day (estimated desloratadine and desloratadine metabolite exposures were approximately 30 times the AUC in humans at the recommended daily oral dose). A significantly higher incidence of hepatocellular tumors (combined adenomas and carcinomas) was observed in males given 10 mg/kg/day of loratadine and in males and females given 25 mg/kg/day of loratadine. The estimated desloratadine and desloratadine metabolite exposures in rats given 10 mg/kg of loratadine were approximately 7 times the AUC in humans at the recommended daily oral dose. The clinical significance of these findings during long-term use of desloratadine is not known.</p><p>&nbsp;</p><p>In a 2-year dietary study in mice, males and females given up to 16 mg/kg/day and 32 mg/kg/day desloratadine, respectively, did not show significant increases in the incidence of any tumors. The estimated desloratadine and desloratadine metabolite exposures in mice at these doses were 12 and 27 times, respectively, the AUC in humans at the recommended daily oral dose.</p><p>&nbsp;</p><p><strong>Genotoxicity Studies:</strong> In genotoxicity studies with desloratadine, there was no evidence of genotoxic potential in a reverse mutation assay (Salmonella/E. coli mammalian microsome bacterial mutagenicity assay) or in 2 assays for chromosomal aberrations (human peripheral blood lymphocyte clastogenicity assay and mouse bone marrow micronucleus assay).</p><p>&nbsp;</p><p><strong>Impairment of Fertility:</strong> There was no effect on female fertility in rats at desloratadine doses up to 24 mg/kg/day (estimated desloratadine and desloratadine metabolite exposures were approximately 130 times the AUC in humans at the recommended daily oral dose). A male-specific decrease in fertility, demonstrated by reduced female conception rates, decreased sperm numbers and motility, and histopathologic testicular changes, occurred at an oral desloratadine dose of 12 mg/kg (estimated desloratadine and desloratadine metabolite exposures were approximately 45 times the AUC in humans at the recommended daily oral dose). Desloratadine had no effect on fertility in rats at an oral dose of 3 mg/kg/day (estimated desloratadine and desloratadine metabolite exposures were approximately 8 times the AUC in humans at the recommended daily oral dose).</p><p>&nbsp;</p><p><strong>5.3.2 Animal Toxicology and/or Pharmacology </strong></p><p><strong>&nbsp;</strong></p><p><strong>Reproductive Toxicology Studies:</strong> Desloratadine was not teratogenic in rats at doses up to 48 mg/kg/day (estimated desloratadine and desloratadine metabolite exposures were approximately 210 times the AUC in humans at the recommended daily oral dose) or in rabbits at doses up to 60 mg/kg/day (estimated desloratadine exposures were approximately 230 times the AUC in humans at the recommended daily oral dose). In a separate study, an increase in pre-implantation loss and a decreased number of implantations and fetuses were noted in female rats at 24 mg/kg (estimated desloratadine and desloratadine metabolite exposures were approximately 120 times the AUC in humans at the recommended daily oral dose). Reduced body weight and slow righting reflex were reported in pups at doses of 9 mg/kg/day or greater (estimated desloratadine and desloratadine metabolite exposures were approximately 50 times or greater than the AUC in humans at the recommended daily oral dose). Desloratadine had no effect on pup development at an oral dose of 3 mg/kg/day (estimated desloratadine and desloratadine metabolite exposures were approximately 7 times the AUC in humans at the recommended daily oral dose).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>For </strong><strong>PSEUDOEPHEDRINE SULFATE 120 MG BULK</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dibasic Calcium Phosphate Dihydrate: 60 mg</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Avicel PH 102: 44.5 mg</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hydroxypropyl Methylcellulose K15M: 105 mg</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Povidone 30: 12 mg</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Purified Water BP Q.S.</p><p><strong>&nbsp;</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Extragranular Materials</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Colloidal Silicon Dioxide: 3.5 mg</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Magnesium Stearate: 5 mg</p><p>&nbsp;</p><p><strong>For DESLORATADINE 2.5 MG BULK</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Avicel PH 101: 47.6 mg</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Maize Starch: 30 mg</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pregelatinized Starch Dry: 15 mg</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Spectracol Brilliant Blue LK 815030: 0.75 mg</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Purified Water BP Q.S.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Extragranular Materials</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pregelatinized Starch Dry: 15 mg</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Avicel PH 112: 36.9 mg</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Colloidal Silicon Dioxide: 1.5 mg</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sodium Stearyl Fumarate: 0.75 mg</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not Applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24Months/2Years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reel PVC/PE/PVDC 250/25/120,&nbsp;95MM Clear blister.</p><p>Each pack contains 20 tablets in 2 strips, each blister contains 10 tablets.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No Special Disposal</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SPIMACO
Al-Qassim Pharmaceutical Plant
Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                March 2024.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>